The European Union is expected to order the gene sequencing giant to divest Grail in the coming days, according to multiple media reports citing unnamed sources familiar with the matter.
The regulator has requested documents and communications related to the acquisition along with certain statements and disclosures about the “conduct and compensation” of certain members of the companies’ management, according to Illumina.
Antitrust regulators argue that Illumina, whose sequencers are being used by companies, hospitals and research centers, could unfairly prioritize Grail in the race to create tests for the early detection of multiple types of cancer. Illumina could raise prices or withhold the technology competing test developers need to thrive.
Gene-sequencing company Pacific BioSciences of California Inc. on Tuesday announced the launch of a new, more affordable, higher-throughput “long-read” sequencer as well as customer testing of its first “short-read” sequencer aimed at emerging markets such as multi-cancer early detection.
Cancer detection test maker Grail, acquired by Illumina Inc. last year despite ongoing antitrust challenges, on Tuesday said it would expand use of its flagship Galleri cancer diagnostic test through a new agreement with life insurer John Hancock, a division of Manulife Financial.
As cases and news of monkeypox spread globally, scientists are investigating the unprecedented outbreak. BioSpace compiled updates about tracking, origins and treatments concerning monkeypox.
Sorry, no posts matched your criteria